Screening for Thyroid Cancer: US Preventive Services Task Force Recommendation Statement
The USPSTF recommends against screening for thyroid cancer in asymptomatic adults, concluding the net benefit is negative.
This USPSTF statement revises prior guidance on thyroid cancer screening. Review of the literature found inadequate direct evidence of benefit yet moderate direct evidence of harm—particularly from overdiagnosis and overtreatment—leading to a negative net benefit and a recommendation against screening asymptomatic adults.
Screening has led to a rise in thyroid cancer incidence without reducing mortality and is associated with significant harms such as unnecessary surgery and treatment for indolent disease.
Evidence level: Korai humán adat. Kis vagy feltáró emberi adat.
Related signals
- The dual axis of tumorigenesis: MAPK and PI3K/AKT pathways in papillary thyroid carcinoma
- The molecular mechanisms and potential therapeutic implications of the crosstalk between DNA methylation and metabolic reprogramming in thyroid cancer
- Improving predicted risk of recurrence using molecular profiling in papillary thyroid cancer
- Global Burden of Thyroid Cancer in Adults Age 15‑49 Years and Its Predictions: Findings From Global Burden of Disease Study 2021
- Thyroid Cancer: Pathogenesis, Clinicopathology, Diagnosis, and Management